Preoperative serum cholesterol is an independent prognostic factor for patients with renal cell carcinoma (RCC)

BJU International

Volumn 115, Issue 3, 2015, Pages 397-404

  De Martino, Michela ^a   Leitner, Carmen V ^a   Seemann, Christoph ^a   Hofbauer, Sebastian L ^a   Lucca, Ilaria ^a   Haitel, Andrea ^b   Shariat, Shahrokh F ^a   Klatte, Tobias ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

cholesterol; concordance; localised; prognosis; regression; survival

Indexed keywords

CHOLESTEROL;

ADULT; AGED; ARTICLE; BODY MASS; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; COLORIMETRY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HUMAN; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PARTIAL NEPHRECTOMY; PREOPERATIVE EVALUATION; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TUMOR NECROSIS; TUMOR VOLUME; BLOOD; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; MIDDLE AGED; PROGNOSIS;

AGED; CARCINOMA, RENAL CELL; CHOLESTEROL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84922980239     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12767     Document Type: Article

References (30)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-1403
2. de Martino M, Klatte T, Seemann C, et al. Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC). BJU Int 2013; 111: E348-353
3. Hamilton RJ, Morilla D, Cabrera F, et al. The association between statin medication and progression after surgery for localized renal cell carcinoma. J Urol 2014; 191: 914-919
4. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281
5. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369: 722-731
6. Choi Y, Park B, Jeong BC, et al. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis. Int J Cancer 2013; 132: 625-634
7. Ko K, Park YH, Lee JW, Ku JH, Kwak C, Kim HH,. Influence of nutritional deficiency on prognosis of renal cell carcinoma (RCC). BJU Int 2013; 112: 775-780
8. Morgan TM, Tang D, Stratton KL, et al. Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol 2011; 59: 923-928
9. Cengiz O, Kocer B, Surmeli S, Santicky MJ, Soran A,. Are pretreatment serum albumin and cholesterol levels prognostic tools in patients with colorectal carcinoma? Med Sci Monit 2006; 12: CR240-247
10. Sherubin EJ, Kannan KS, Kumar DN, Joseph I,. Estimation of plasma lipids and its significance on histopathological grades in oral cancer: prognostic significance an original research. J Oral Maxillofac Pathol 2013; 17: 4-9
11. Ohno Y, Nakashima J, Nakagami Y, et al. Clinical implications of preoperative serum total cholesterol in patients with clear cell renal cell carcinoma. Urology 2014; 83: 154-158
12. Lee CK, Marschner IC, Simes RJ, et al. Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus. Clin Cancer Res 2012; 18: 3188-3196
13. Mickisch G, Carballido J, Hellsten S, Schulze H, Mensink H,. Guidelines on renal cell cancer. Eur Urol 2001; 40: 252-255
14. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H,. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score. J Urol 2002; 168: 2395-2400
15. Karakiewicz PI, Briganti A, Chun FK, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 2007; 25: 1316-1322
16. Klatte T, Remzi M, Zigeuner RE, et al. Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma. J Urol 2010; 184: 53-58
17. de Martino M, Haitel A, Schatzl G, Klatte T,. The protease activated receptor 1 gene variation IVSn -14 A>T is associated with distant metastasis and cancer specific survival in renal cell carcinoma. J Urol 2013; 190: 1392-1397
18. de Martino M, Hoetzenecker K, Ankersmit HJ, et al. Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis. Br J Cancer 2012; 106: 904-908
19. de Martino M, Klatte T, Haitel A, Marberger M,. Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. Cancer 2012; 118: 82-90
20. de Martino M, Haitel A, Schatzl G, Klingler HC, Klatte T,. The CASP8 -652 6N insertion/deletion promoter polymorphism is associated with renal cell carcinoma risk and metastasis. J Urol 2013; 190: 717-722
21. de Martino M, Pantuck AJ, Hofbauer S, et al. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. J Urol 2013; 190: 1999-2004
22. Matsumoto K, Fujiwara Y, Nagai R, Yoshida M, Ueda S,. Expression of two isozymes of acyl-coenzyme A: cholesterol acyltransferase-1 and -2 in clear cell type renal cell carcinoma. Int J Urol 2008; 15: 166-170
23. Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, Remaley AT,. High-density lipoprotein and prostate cancer: an overview. J Epidemiol 2013; 23: 313-319
24. Zhang GM, Zhu Y, Luo L, et al. Prevalence of dyslipidemia in patients with renal cell carcinoma: a case-control study in China. BJU Int 2014; 113: E75-81
25. Klatte T, Han KR, Said JW, et al. Pathobiology and prognosis of chromophobe renal cell carcinoma. Urol Oncol 2008; 26: 604-609
26. Fang Z, Tang Y, Fang J, et al. Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. Plos ONE 2013; 8: e62823
27. Liu W, Choueiri TK, Cho E,. Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts. Cancer 2012; 118: 797-803
28. Manoukian GE, Tannir NM, Jonasch E, Qiao W, Haygood TM, Tu SM,. Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2011; 9: 81-88
29. Chao C, Jacobsen SJ, Xu L, Wallner LP, Porter KR, Williams SG,. Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy. BJU Int 2013; 111: 954-962
30. Crivelli JJ, Xylinas E, Kluth LA, et al. Effect of statin use on outcomes of non-muscle-invasive bladder cancer. BJU Int 2013; 112: E4-12